Neuropsychiatric Lupus Erythematosus
Neuropsychiatric involvement in patients with Systemic Lupus Erythematosus (SLE), first mentioned by Kaposi more than 100 years ago, still remains one of the main challenge facing rheumatologist and other physicians. The diagnosis of neuropsychiatric SLE (NPSLE) is complex not only because of the co...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-09-01
|
| Series: | Reumatismo |
| Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/266 |
| _version_ | 1818187003945025536 |
|---|---|
| author | A. Palma Modoni G. Coppolino A. Rigon F. Buzzulini M. Vadacca R. Massa A. Afeltra |
| author_facet | A. Palma Modoni G. Coppolino A. Rigon F. Buzzulini M. Vadacca R. Massa A. Afeltra |
| author_sort | A. Palma Modoni |
| collection | DOAJ |
| description | Neuropsychiatric involvement in patients with Systemic Lupus Erythematosus (SLE), first mentioned by Kaposi more than 100 years ago, still remains one of the main challenge facing rheumatologist and other physicians. The diagnosis of neuropsychiatric SLE (NPSLE) is complex not only because of the considerable prevalence variation (14-80%) but also because of the wide spectrum of NP manifestations. They vary from overt neurologic alterations (seizure, psychosis), to subtle abnormalities (neurocognitive dysfunctions). Different NP manifestations result from a variety of mechanisms including antibodies, vasculitis, thrombosis, hemorrhages and cytokine-mediated damages. Of note, despite the dramatic clinical manifestations, too often changes at the morphological neuroimaging techniques are minimal and non specific. There is no one diagnostic tool specific for NPSLE and diagnosis must be based on the combinated use of immunoserological tests, functional and anatomical neuroimaging and standardized specific criteria. Symptomatic, immunosuppressive and anticoagulant therapies are the main strategies available in the management of these patients. Therapy for CNS lupus should be adjusted according to the needs of the individual patients. The coming years promise to be an important time for the development of new neuroimaging techniques and for the study of disease mechanism. An early and objective identification of brain involvement will allow for appropriate treatment to avoid severe complications. |
| first_indexed | 2024-12-11T23:04:08Z |
| format | Article |
| id | doaj.art-d88581072a1340788d9e0beeae2b4d3d |
| institution | Directory Open Access Journal |
| issn | 0048-7449 2240-2683 |
| language | English |
| last_indexed | 2024-12-11T23:04:08Z |
| publishDate | 2011-09-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Reumatismo |
| spelling | doaj.art-d88581072a1340788d9e0beeae2b4d3d2022-12-22T00:46:59ZengPAGEPress PublicationsReumatismo0048-74492240-26832011-09-0158317718610.4081/reumatismo.2006.177Neuropsychiatric Lupus ErythematosusA. Palma ModoniG. CoppolinoA. RigonF. BuzzuliniM. VadaccaR. MassaA. AfeltraNeuropsychiatric involvement in patients with Systemic Lupus Erythematosus (SLE), first mentioned by Kaposi more than 100 years ago, still remains one of the main challenge facing rheumatologist and other physicians. The diagnosis of neuropsychiatric SLE (NPSLE) is complex not only because of the considerable prevalence variation (14-80%) but also because of the wide spectrum of NP manifestations. They vary from overt neurologic alterations (seizure, psychosis), to subtle abnormalities (neurocognitive dysfunctions). Different NP manifestations result from a variety of mechanisms including antibodies, vasculitis, thrombosis, hemorrhages and cytokine-mediated damages. Of note, despite the dramatic clinical manifestations, too often changes at the morphological neuroimaging techniques are minimal and non specific. There is no one diagnostic tool specific for NPSLE and diagnosis must be based on the combinated use of immunoserological tests, functional and anatomical neuroimaging and standardized specific criteria. Symptomatic, immunosuppressive and anticoagulant therapies are the main strategies available in the management of these patients. Therapy for CNS lupus should be adjusted according to the needs of the individual patients. The coming years promise to be an important time for the development of new neuroimaging techniques and for the study of disease mechanism. An early and objective identification of brain involvement will allow for appropriate treatment to avoid severe complications.http://www.reumatismo.org/index.php/reuma/article/view/266 |
| spellingShingle | A. Palma Modoni G. Coppolino A. Rigon F. Buzzulini M. Vadacca R. Massa A. Afeltra Neuropsychiatric Lupus Erythematosus Reumatismo |
| title | Neuropsychiatric Lupus Erythematosus |
| title_full | Neuropsychiatric Lupus Erythematosus |
| title_fullStr | Neuropsychiatric Lupus Erythematosus |
| title_full_unstemmed | Neuropsychiatric Lupus Erythematosus |
| title_short | Neuropsychiatric Lupus Erythematosus |
| title_sort | neuropsychiatric lupus erythematosus |
| url | http://www.reumatismo.org/index.php/reuma/article/view/266 |
| work_keys_str_mv | AT apalmamodoni neuropsychiatriclupuserythematosus AT gcoppolino neuropsychiatriclupuserythematosus AT arigon neuropsychiatriclupuserythematosus AT fbuzzulini neuropsychiatriclupuserythematosus AT mvadacca neuropsychiatriclupuserythematosus AT rmassa neuropsychiatriclupuserythematosus AT aafeltra neuropsychiatriclupuserythematosus |